Inactive Instrument

Highlights Lannett Company, Inc.

Stocks

LCI

US5160122009

Pharmaceuticals

Highlights

07-10	Lannett Company Recalls Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate And Amphetamine Sulfate Extended-Release Capsules Due To Label Mix-Up	CI
06-28	Aurobindo Pharma USA, Inc. completed the acquisition of Lannett Company, Inc.	CI
06-24	Aurobindo Pharma Limited and Lannett Company Inc Federal Trade Commission Proposes Settlement Requiring Divestiture of Generic Drug Products	CI
05-29	Lannett Company, Inc Recalls Primidone Tablets USP 250mg Due To Cross Contamination	CI
25-07-29	Aurobindo Pharma USA, Inc. entered into a definitive agreement to acquire Lannett Company, Inc. in a transaction valued at $250 million.	CI
23-05-15	Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-04-04	Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial	CI
23-02-01	Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M	MT
23-02-01	Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34	MT
23-02-01	Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
23-02-01	Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023	CI
23-01-26	Lannett to Implement 1-for-4 Reverse Stock Split	MT
23-01-04	Lannett Company Provides Development Update on Biosimilar Insulin Products	CI
22-11-02	Earnings Flash (LCI) LANNETT COMPANY Posts Q1 Loss $-0.42	MT
22-11-02	Earnings Flash (LCI) LANNETT COMPANY Reports Q1 Revenue $75.1M	MT
22-11-02	Lannett Company, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
22-11-02	Lannett Company, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023	CI
22-10-21	Lannett Company, Inc. Receives FDA Approval to Manufacture Numbrino® at Seymour Plant	CI
22-10-19	Lannett Sells Several Discontinued New Drug Applications to Unnamed Company for $3 Million	MT
22-08-31	Lannett Company, Inc. Announces Subject Dosing Complete for Pivotal Clinical Trial of Biosimilar Insulin Glargine	CI
22-08-24	Lannett Co Q4 Loss Widens Amid Lower Revenue, Issues Guidance	MT
22-08-24	Earnings Flash (LCI) LANNETT COMPANY Reports Q4 Loss $-0.44	MT
22-08-24	Earnings Flash (LCI) LANNETT COMPANY Posts Q4 Revenue $74.2M	MT
22-08-24	Lannett Company, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2022	CI
22-08-24	Lannett Company, Inc. Provides Earnings Guidance for the Fiscal Year 2023	CI